Cormorant Asset Management, LP Vectiv Bio Holding Ag Transaction History

Cormorant Asset Management, LP

$1.43 Billion
Q3 2024

Shares

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$4.7 - $6.07 $1.43 Million - $1.84 Million	-303,772 Reduced 10.69%	2,536,617 $15.2 Million
Q2 2022 Aug 15, 2022	BUY	$4.2 - $6.55 $3.2 Million - $4.99 Million	761,904 Added 36.66%	2,840,389 $15.3 Million
Q1 2022 May 16, 2022	SELL	$4.6 - $5.8 $636,078 - $802,012	-138,278 Reduced 6.24%	2,078,485 $9.79 Million
Q4 2021 Feb 14, 2022	SELL	$2.83 - $7.26 $26,502 - $67,989	-9,365 Reduced 0.42%	2,216,763 $10.9 Million
Q2 2021 Aug 16, 2021	BUY	$11.66 - $24.23 $26 Million - $53.9 Million	2,226,128 New	2,226,128 $25.5 Million

Others Institutions Holding VECT

# of Institutions

1

Shares Held

510K

Call Options Held

0

Put Options Held

0

Regency Capital Management Inc.\De

510K
Shares

$0
0.0% of portfolio

About VectivBio Holding AG

Ticker VECT
Exchange NASDAQ
Description
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with sho...

More about VECT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.